Difficulty: Medium
Average Score: 89%
Practice
True statement (s) concerning octreotide:
Correct answer
D
Rationale
In this question, the correct answer is option D) A and C.
Rationale:
A) Octreotide is a long-acting somatostatin analog. Somatostatin is a hormone that inhibits the release of several hormones, including growth hormone (GH), gastrointestinal hormones, and glucagon. By acting as an analog of somatostatin, octreotide helps to regulate the release of these hormones.
C) Octreotide is effective against gastrointestinal tumors that secrete various hormones such as vasoactive intestinal peptide (VIP), gastrin, and glucagon. These tumors, known as VIPomas, gastrinomas, and glucagonomas, can be managed effectively with octreotide due to its ability to inhibit the secretion of these hormones.
Why the other options are wrong:
B) Option B is incorrect because octreotide does not stimulate the release of GH, gastrointestinal hormones, or glucagon. Instead, it inhibits the release of these hormones by acting as a somatostatin analog.
Educational context:
Understanding the pharmacological properties of octreotide is crucial in the treatment of patients with conditions such as acromegaly, carcinoid syndrome, and certain types of neuroendocrine tumors. By knowing that octreotide is a long-acting somatostatin analog and its effectiveness against specific tumor types, healthcare providers can make informed decisions regarding its use in clinical practice. This knowledge helps in optimizing patient outcomes and managing potential side effects associated with octreotide therapy.
Rationale:
A) Octreotide is a long-acting somatostatin analog. Somatostatin is a hormone that inhibits the release of several hormones, including growth hormone (GH), gastrointestinal hormones, and glucagon. By acting as an analog of somatostatin, octreotide helps to regulate the release of these hormones.
C) Octreotide is effective against gastrointestinal tumors that secrete various hormones such as vasoactive intestinal peptide (VIP), gastrin, and glucagon. These tumors, known as VIPomas, gastrinomas, and glucagonomas, can be managed effectively with octreotide due to its ability to inhibit the secretion of these hormones.
Why the other options are wrong:
B) Option B is incorrect because octreotide does not stimulate the release of GH, gastrointestinal hormones, or glucagon. Instead, it inhibits the release of these hormones by acting as a somatostatin analog.
Educational context:
Understanding the pharmacological properties of octreotide is crucial in the treatment of patients with conditions such as acromegaly, carcinoid syndrome, and certain types of neuroendocrine tumors. By knowing that octreotide is a long-acting somatostatin analog and its effectiveness against specific tumor types, healthcare providers can make informed decisions regarding its use in clinical practice. This knowledge helps in optimizing patient outcomes and managing potential side effects associated with octreotide therapy.